HARMONY BIOSCIENCES
Plymouth Meeting, Pennsylvania, United States · Biopharma, Biotechnology, Health Care
At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that where empathy and innovation meet, a better life can begin for people living with neurological diseases. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, our team of experts from a wide variety of discipl
Key facts
- Headquarters
- Plymouth Meeting, Pennsylvania, United States
- Employees
- 344
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (HRMY)
- Website
- harmonybiosciences.com
- Company page
Recent activity at HARMONY BIOSCIENCES
- : Peter Anastasiou Appointed as CEO of Harmony Biosciences
- : Harmony Biosciences Appoints Peter Anastasiou as Chief Executive Officer
- : SEC 8-K (5.02): On October 12, 2026, Harmony Biosciences Holdings, Inc. announced the departure of Jeffrey M. Dayno, M.D., as President and CEO, effective December 31, 2026, as part of a leadership succession plan. Concurrently, Peter Anastasiou, the current COO, was appointed as the new President and CEO, effective January 1, 2027. Anastasiou, age 55, has an extensive background in the pharmaceutical industry, including previous roles at Capsida Biotherapeutics and Lundbeck. His appointment coincides with Dayno stepping down from the Board of Directors, creating a vacancy that Anastasiou will fill, serving a term expiring at the Company’s 2027 Annual Meeting of Stockholders.
- : SEC 8-K (7.01): On August 4, 2026, Harmony Biosciences filed a Regulation FD Disclosure regarding an investor presentation posted to their website. This presentation is intended for use in discussions with investors and analysts. The filing includes a caution about forward-looking statements and emphasizes that the information is summary in nature. The presentation aims to provide insight into the company's future outlook and performance, while the company reserves the right to update the information as necessary. The posting is crucial for maintaining transparency with stakeholders about strategic updates and operational insights.
- : Harmony Biosciences Appoints Stephen Mollichella as Interim CFO
- : SEC 8-K (5.02): On July 16, 2026, Glenn Reicin resigned from his position as Chief Financial Officer of the Company to pursue other career opportunities. His departure was formalized through a Separation Agreement with Harmony Biosciences Management, Inc., which grants him severance payments and a pro-rated bonus in exchange for a release of claims. Additionally, Stephen Mollichella was appointed as the Interim Principal Financial Officer effective the same day. Mr. Mollichella, who has been with the Company since 2021, has extensive finance and accounting leadership experience. The disclosures were announced in a press release on July 16, 2026, highlighting significant changes in the executive leadership of the Company.
- : SEC 8-K (7.01): On May 7, 2026, Harmony Biosciences posted an investor presentation on their website, which is expected to be utilized for various presentations to investors and analysts. This presentation contains summary information derived from the Company’s SEC filings and announcements. The filing indicates the Company may modify the presentation before use and highlights the forward-looking statements included in it, addressing inherent risks and uncertainties. The filing seeks to provide context to investors regarding the Company's future strategies and performance expectations.
- : SEC 8-K (5.02): Harmony Biosciences Holdings, Inc. announced on April 14, 2026, that Sandip Kapadia is departing from his role as Chief Financial Officer effective immediately to pursue other career opportunities. In conjunction with his departure, a Separation Agreement was executed on the same date, which stipulates severance payments and conditions for Mr. Kapadia. Additionally, Glenn Reicin has been appointed as the new Chief Financial Officer, also effective April 14, 2026. Reicin, a seasoned executive with extensive experience in the biotech sector, previously held CFO positions at Eccogene and Alladapt Immunotherapeutics. His appointment includes an Executive Employment Agreement outlining his compensation and terms of employment, further solidifying the leadership transition within the company.
- : Harmony Biosciences Appoints Peter Anastasiou as Chief Operating Officer
- : SEC 8-K (5.02): On April 2, 2026, Harmony Biosciences Holdings, Inc. appointed Peter Anastasiou as the Senior Executive Vice President and Chief Operating Officer (COO). Simultaneously, he resigned from his position as a Class III director on the Company's board, effective the same day. His resignation was amicable and not due to any disagreements with the Company. Mr. Anastasiou's Executive Employment Agreement entitles him to an annual base salary of $600,000 and a target annual bonus of 55%, effective April 2, 2026. His extensive experience includes previous leadership roles at Capsida Biotherapeutics and Lundbeck, which will influence Harmony's strategic direction under his guidance.
Leadership
- Ellen Mancino, Associate Director, Talent Acquisition
- Jeffrey M. Dayno, M.D., Chief Executive Officer
- Peter Anastasiou, Chief Executive Officer
- Peter Anastasiou, Chief Executive Officer
- Stephen Mollichella, Principal
- Peter Anastasiou, Chief Operating Officer
- Jeffrey Dayno, President
Verified email and direct lines for HARMONY BIOSCIENCES’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
HARMONY BIOSCIENCES files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Oct 2026.
HARMONY BIOSCIENCES in the news
Companies similar to HARMONY BIOSCIENCES
- Renibus Therapeutics · Biopharma, Biotechnology, Health Care, Medical, Therapeutics
- Aquestive Therapeutics, Inc. · Biopharma, Biotechnology, Health Care, Medical, Therapeutics
- Hansa Biopharma · Biopharma, Biotechnology, Health Care, Medical, Therapeutics
- Abivax · Biopharma, Biotechnology, Health Care, Medical, Therapeutics
- NRx Pharmaceuticals · Biopharma, Biotechnology, Health Care, Medical, Therapeutics
About HARMONY BIOSCIENCES: questions and answers
What does HARMONY BIOSCIENCES do?
At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that where empathy and innovation meet, a better life can begin for people living with neurological diseases. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, our team of experts from a wide variety of discipl
Where is HARMONY BIOSCIENCES headquartered?
HARMONY BIOSCIENCES is headquartered in Plymouth Meeting, Pennsylvania, United States.
How many employees does HARMONY BIOSCIENCES have?
HARMONY BIOSCIENCES has about 344 employees.
Who leads HARMONY BIOSCIENCES?
Jeffrey M. Dayno, M.D. is a Chief Executive Officer at HARMONY BIOSCIENCES.
What is the latest news on HARMONY BIOSCIENCES?
On Oct 13, 2026, Peter Anastasiou Appointed as CEO of Harmony Biosciences
Is HARMONY BIOSCIENCES a public company?
Yes. HARMONY BIOSCIENCES is publicly traded under the ticker HRMY.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy